Signadori Bio
Business Services · France · 1-10 Employees
View Company Info for Free
Overview
Headquarters
7-11 Boulevard Haussmann, Paris, Ile-de-...Website
www.signadoribio.comRevenue
<$5 MillionIndustry
ZI Rank: 1
Signal Type
Jan
Feb
Mar
Apr
May
Jun
ZI Rank
1
1
1
1
1
1
About Signadori Bio
Signadori Bio is a preclinical-stage biopharmaceutical company developing a next generation, off-the shelf, in vivo engineered, monocyte immunotherapy platform to treat solid tumours. Founded by Dr Jean-Luc Perfettini and Professor Nathalie Chaput, and based on research conducted at Gustave Roussy, Signadori’s approach aims to overcome the challenges of the tumour microenvironment by harnessing the immune potential of gene-modified monocytes. Signadori is based in Paris and backed by Sofinnova Partners.Explore more
Signadori Bio Org Chart
Get the full picture
Sign in to uncover key details.
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Signadori Bio your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Product Launch: Get notified when Signadori Bio launches new products
Check if Signadori Bio has recently received funding, and reach out quickly before it becomes old news!
Check out if Signadori Bio is spiking on competitors!
Website visits: Recent activity has been detected on your website
Congratulate Masked Content for being promoted to Masked Content at Signadori Bio
Signadori Bio, which may be a good buyer, showed buying intent in Masked Content Topic
Earning: See what the market has to say on Signadori Bio recently announced quarterly report
Funding: Get notified immidiatlly once Signadori Bio has new funding data
Click to see if Signadori Bio had a recent Job posting/layoffs
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Recommended Actions
Reach out to Masked Content who joined Signadori Bio as Masked Content
Find more new buyers
Company Profile Activity
Activity Insights
Signadori Bio is experiencing very low activity levels compared to other companies in the Business Services sector.
What does this means?
Signadori Bio is drawing exceptional interest within the Business Services industry, suggesting notable developments or strong market momentum, learn more about Signadori Bio.
Most Recent Scoops
Funding
Funding
New Hire
Executive Move
Executive Moves, New Hire
Lateral Move
Executive Move
Executive Moves, Lateral Move, Board of Directors
Lateral Move
Executive Move
Signadori Bio News & Media
Signadori Bio appoints Dr. Selwyn Ho, MB BS as Chief Executive Officer to lead company ...
Dr. Selwyn Ho takes over from Matthieu Coutet, Partner at Sofinnova Partners, who will move into the role of Chair of the Board at Signadori Bio Transition follows promising pre-clinical proof of concept data demonstrating potent cancer cell killing across multiple cancer types using Signadori Bio’s core immunotherapy technology, engineering monocytes to express P21 (CDKN1A), a master regulator of myeloid anti-tumour activity (ANSA)
Read more news
Top Business Services Companies
Top companies in Australia by revenue
Frequently Asked Questions Regarding Signadori Bio
Sign Up For FreeTo access detailed company insights
Signadori Bio is a preclinical-stage biopharmaceutical company developing a next generation, off-the shelf, in vivo engineered, monocyte immunotherapy platform to treat solid tumours. Founded by Dr Jean-Luc Perfettini and Professor Nathalie Chaput, and based on research conducted at Gustave Roussy, Signadori’s approach aims to overcome the challeng... Read More
